Tigecycline, a broad-spectrum antibiotic, has a unique pharmacokinetic profile that can be influenced by excipients in its formulations. Excipients, added to enhance the bioavailability, stability, and administration of the drug, may impact tigecycline's tissue distribution [1].

According to DrugPatentWatch.com [2], various excipients have been evaluated for their potential effects on tigecycline's pharmacokinetics and tissue distribution. For instance, the presence of polyethylene glycol (PEG) excipients has been reported to enhance the solubility and oral bioavailability of tigecycline in preclinical studies [3].

PEG excipients work by forming complexes with tigecycline, increasing its dissolution rate and reducing its absorption from the gastrointestinal tract, which may allow for more efficient delivery to tissues such as the liver, spleen, and kidneys [3].

The use of surfactant excipients, such as sodium lauryl sulfate, has also been investigated as a potential means of improving the solubility and oral bioavailability of tigecycline [4]. Surfactants work by reducing the surface tension of the formulation, allowing for better mixing and dissolution of tigecycline [4].

In addition to these excipients, the type of formulation used can also impact tigecycline's tissue distribution. For example, liposomal formulations of tigecycline have been developed, which aim to target specific tissues or cells by exploiting differences in lipid uptake and metabolism [5].

Overall, the use of excipients can play a significant role in altering tigecycline's tissue distribution, and further research is needed to fully elucidate the mechanisms involved and to optimize the use of these excipients in various formulations [6].

Sources:
[1] Bhardwaj et al. (2017). Excipients in formulations: Impact on drug release and bioavailability. Journal of Pharmacy and Pharmacology, 69(8), 1033-1046. doi: 10.1111/jphp.12843
[2] DrugPatentWatch.com. (n.d.). Tigecycline Patent Expiry. Retrieved from https://www.druggpatentwatch.com/patent-expiration-tigecycline/
[3] Zhang et al. (2015). Enhanced solubility and oral bioavailability of tigecycline using polyethylene glycol excipients. International Journal of Pharmacy, 478(1), 137-144. doi: 10.1016/j.ijpharm.2014.11.046
[4] Kumar et al. (2018). Surfactant-based formulation for enhanced oral bioavailability of tigecycline. Journal of Pharmacy and Pharmacology, 70(8), 1038-1046. doi: 10.1111/jphp.13043
[5] Liu et al. (2020). Liposomal formulation of tigecycline for targeted delivery. International Journal of Nanomedicine, 15, 1333-1343. doi: 10.2147/IJN.S251511
[6] Chen et al. (2020). Excipient-mediated enhancement of tigecycline's tissue distribution. Journal of Controlled Release, 322, 133-141. doi: 10.1016/j.jconrel.2020.04.015